{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:34:44Z","timestamp":1778632484783,"version":"3.51.4"},"reference-count":54,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The human epidermal growth factor receptor 2 (HER2) represents one of the most studied tumor-associated antigens for cancer immunotherapy. The receptors for HER2 are overexpressed in various human cancers, such as breast and ovarian cancer. The relatively low expression of this antigen on normal tissues makes it a clinically useful molecular target for tumor imaging and targeted therapy. HER2 overexpression is correlated with aggressive tumor behavior and poor clinical outcomes. Thus, HER2 has become an important prognostic and predictive factor, as well as a potential molecular target. Due to the heterogeneity of breast cancer and possible discordance in HER2 status between primary tumors and distant metastases, assessment of HER2 expression by noninvasive imaging is important. Molecular imaging of HER2 expression may provide essential prognostic and predictive information concerning disseminated cancer and aid in the selection of an optimal therapy. Another tumor-specific antigen is MUC1, which is silent on normal tissues, but overexpressed in almost all human epithelial cell cancers, including &gt;90% of human breast, ovarian, pancreatic, colorectal, lung, prostate, and gastric cancers and is a promising tumor antigen with diagnostic as well as the therapeutic potential of cancer. Radiolabeled small peptide ligands are attractive as probes for molecular imaging, as they reach and bind the target receptor efficiently and clear from blood and non-target organs faster than bulky antibodies. In this study, HER2 and MUC1-based peptides were synthesized and preclinically evaluated in an effort to develop peptide-based SPECT radiopharmaceuticals derived from tumor-associated antigens for the detection of breast cancer. Our findings demonstrate that the tumor antigen peptides radiolabeled efficiently with 99mTc and showed high metabolic stability in human plasma in vitro. The data from breast tumor cell binding confirmed the high affinity (in low nanomolar range) towards respective breast cancer cell lines. In healthy mice, 99mTc-labeled peptides displayed favorable pharmacokinetics, with high excretion by the renal system. In tumor xenografts nude mice models, good uptake by the SKBR3, MCF7, and T47D tumors were found, with good tumor-to-blood and tumor to muscle ratios. Additionally, tumor lesions can be seen in \u03b3-camera imaging. Our data suggest that based on its ability to detect HER2- and MUC1-positive breast cancer cells in vivo, 99mTc-HER2 and 99mTc-MUC1-targeted peptides may be promising tumor imaging probes and warrant further investigation.<\/jats:p>","DOI":"10.3390\/molecules24173142","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T11:26:22Z","timestamp":1567077982000},"page":"3142","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas"],"prefix":"10.3390","volume":"24","author":[{"given":"Subhani M.","family":"Okarvi","sequence":"first","affiliation":[{"name":"Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"AlJammaz","sequence":"additional","affiliation":[{"name":"Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Alatrash, G., and Molldrem, J.J. (2013). Tumor-associated antigens. In Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Elsevier Inc.","DOI":"10.1016\/B978-0-12-416004-0.00007-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","article-title":"Antigens for cancer immunotherapy","volume":"20","author":"Neller","year":"2008","journal-title":"Semin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.2967\/jnumed.115.157941","article-title":"Imaging diagnostic and therapeutic targets: Human epidermal growth factor receptor 2","volume":"57","author":"Gebhart","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ijc.20306","article-title":"Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells","volume":"111","author":"Pero","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7150\/thno.14302","article-title":"HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery","volume":"6","author":"Geng","year":"2016","journal-title":"Theranostics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/CCO.0b013e32833f8c3a","article-title":"Molecular imaging of HER2-positive breast cancer\u2014A step toward an individualized \u201cImage and Treat\u201d strategy","volume":"22","author":"Capala","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.03.012","article-title":"Hormone Receptor\/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going","volume":"46","author":"Schettini","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/IJN.S113607","article-title":"Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells","volume":"12","author":"Ringhieri","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01.HP.0000334064.46217.20","article-title":"Combined imaging modalities: PET\/CT and SPECT\/CT","volume":"95","author":"Maurer","year":"2008","journal-title":"Health Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7150\/thno.4024","article-title":"Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer","volume":"2","author":"Fani","year":"2012","journal-title":"Theranostics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40336-019-00326-3","article-title":"Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: An overview","volume":"7","author":"Okarvi","year":"2019","journal-title":"Clin. Transl. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/1535-7163.MCT-12-0357","article-title":"HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo","volume":"12","author":"Kawamoto","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.3816\/CBC.2009.s.005","article-title":"Treatment of HER2-positive metastatic breast cancer following initial progression","volume":"9","author":"Mayer","year":"2009","journal-title":"Clin. Breast Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1758834015599389","article-title":"Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: How the latest results are improving therapeutic options","volume":"7","author":"Jiang","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2967\/jnumed.116.183863","article-title":"SPECT\/CT imaging of the novel HER2-targeted peptide probe 99mTc-HYNIC-H6F in breast cancer mouse models","volume":"58","author":"Li","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/bcr3674","article-title":"Construction and evaluation of a novel humanized HER2-specific chimeric receptor","volume":"16","author":"Sun","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1248\/cpb.c17-00098","article-title":"Peptide-Based Cancer-Targeted DDS and Molecular Imaging","volume":"65","author":"Hagimori","year":"2017","journal-title":"Chem. Pharm. Bull."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1021\/cr900317f","article-title":"Phage display in molecular imaging and diagnosis of cancer","volume":"110","author":"Deutscher","year":"2010","journal-title":"Chem. Rev."},{"key":"ref_19","first-page":"693","article-title":"In Vitro and in Vivo Evaluation of 64Cu-Radiolabeled KCCYSL Peptides for Targeting Epidermal Growth Factor Receptor-2 in Breast Carcinomas","volume":"25","author":"Kumar","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/mp3002717","article-title":"Masking and Triggered Unmasking of Targeting Ligands on Liposomal Chemotherapy Selectively Suppress Tumor Growth in Vivo","volume":"10","author":"Bandekar","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_21","first-page":"3981","article-title":"Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging","volume":"7","author":"Jie","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_22","first-page":"4","article-title":"Biacore analysis of rationally designed anti-HER2 exocytic mimetics of antibodies","volume":"8","author":"Berezov","year":"2001","journal-title":"BIAjournal"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.nano.2016.07.013","article-title":"HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug","volume":"13","author":"Ding","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/72651","article-title":"Rationally designed anti-HER2\/neu peptide mimetic disables P185HER2\/neu tyrosine kinases in vitro and in vivo","volume":"18","author":"Park","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12967-018-1550-3","article-title":"Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo","volume":"16","author":"Guan","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1038\/s41598-018-21283-3","article-title":"Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe","volume":"8","author":"Honarvar","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_27","first-page":"2823","article-title":"Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas","volume":"38","author":"Okarvi","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.26574","article-title":"Clinical trial results of the HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients","volume":"118","author":"Mittendorf","year":"2012","journal-title":"Cancer"},{"key":"ref_29","first-page":"4192","article-title":"Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals","volume":"6","author":"Anderson","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: Function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"Muc1: A multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/oxfordjournals.jbchem.a022759","article-title":"Molecular mimicry of human tumor antigen by heavy chain CDR3 sequence of the anti-idiotypic antibody","volume":"128","author":"Luo","year":"2000","journal-title":"J. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1073\/pnas.1115166109","article-title":"Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine","volume":"109","author":"Lakshminarayanan","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/1535-7163.MCT-06-0604","article-title":"Target specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors","volume":"6","author":"Singh","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1038\/sj.onc.1207713","article-title":"MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation","volume":"23","author":"Schroeder","year":"2004","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1023\/A:1011379725811","article-title":"MUC1, the renaissance molecule","volume":"6","author":"Gendler","year":"2001","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"ref_37","first-page":"677","article-title":"Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen","volume":"27","author":"Movahedin","year":"2017","journal-title":"Glycobiology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3389\/fimmu.2018.02391","article-title":"MUC1 Mucin: A Putative Regulatory (Checkpoint) Molecule of T Cells","volume":"9","author":"Agrawal","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1182\/blood.V93.12.4309","article-title":"Identification of HLA-A2\u2013Restricted T-Cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies","volume":"93","author":"Brossart","year":"1999","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.1074\/jbc.M103187200","article-title":"Identification and topology of variant Sequences within individual repeat domains of the human epithelial tumor Mucin MUC1","volume":"276","author":"Engelmann","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/ijc.2910430620","article-title":"A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas","volume":"43","author":"Girling","year":"1989","journal-title":"Int. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.4049\/jimmunol.142.10.3503","article-title":"Reactivity of anti-human milk fat globule antibodies with synthetic peptides","volume":"142","author":"King","year":"1989","journal-title":"J. Immunol."},{"key":"ref_43","first-page":"89","article-title":"Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies","volume":"50","author":"Xing","year":"1990","journal-title":"Cancer Res."},{"key":"ref_44","first-page":"2856","article-title":"Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients","volume":"54","author":"Kotera","year":"1994","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.nucmedbio.2016.03.006","article-title":"Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma","volume":"43","author":"Okarvi","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.bjc.6601267","article-title":"An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells","volume":"89","author":"Heuser","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_47","first-page":"255","article-title":"Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro","volume":"58","author":"Walsh","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_48","unstructured":"(1996). Guide for the Care and Use of Laboratory Animals, National Academy Press."},{"key":"ref_49","first-page":"1650","article-title":"Preclinical comparison of 111In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy","volume":"43","author":"Breeman","year":"2002","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.202162199","article-title":"External control of HER2 expression and cancer cell growth by targeting a Ras-linked coactivator","volume":"99","author":"Asada","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","first-page":"811","article-title":"Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor \u00df1","volume":"19","author":"Lattrich","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10895-014-1486-9","article-title":"Synthesis and characterization of HER2-NLP peptide conjugates targeting circulating breast cancer cells: Cellular uptake and localization by fluorescent microscopic imaging","volume":"25","author":"Cai","year":"2015","journal-title":"J. Fluoresc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/1078-0432.CCR-04-1636","article-title":"In Vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter","volume":"11","author":"Dwyer","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nucmedbio.2009.12.006","article-title":"Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors","volume":"37","author":"Okarvi","year":"2010","journal-title":"Nucl. Med. Biol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/17\/3142\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:14:52Z","timestamp":1760188492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/17\/3142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":54,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["molecules24173142"],"URL":"https:\/\/doi.org\/10.3390\/molecules24173142","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]}}}